Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Molecules ; 25(9)2020 04 30.
Article in English | MEDLINE | ID: mdl-32366049

ABSTRACT

: Sarcopenia is a clinical problem associated with several pathological and non-pathological conditions. The aim of the present research is the evaluation of the pharmacological profile of the leucine metabolite ß-hydroxy-ß-methyl butyrate (HMB) associated with the natural R(+) stereoisomer of lipoic acid (R(+)LA) in a cellular model of muscle wasting. The C2C12 cell line is used as myoblasts or is differentiated in myotubes, sarcopenia is induced by dexamethasone (DEX). A Bonferroni significant difference procedure is used for a post hoc comparison. DEX toxicity (0.01-300 µM concentration range) is evaluated in myoblasts to measure cell viability and caspase 3 activation after 24 h and 48 h; cell incubation with 1 µM DEX for 48 h is chosen as optimal treatment for decreasing cell viability and increasing caspase 3 activity. R(+)LA or HMB significantly prevents DEX-induced cell mortality; the efficacy is improved when 100 µM R(+)LA is combined with 1 mM HMB. Regarding myoblasts, this combination significantly reduces DEX-evoked O2- production and protein oxidative damage. During the early phase of myotube formation, the mixture preserves the number of myogenin-positive cells, whereas it completely prevents the DEX-dependent damage in a later phase of myotube differentiation (7 days), as evaluated by cell diameter and percentage of multinucleated cells. R(+)LA in association with HMB is suggested for sarcopenia therapy.


Subject(s)
Muscle Fibers, Skeletal/drug effects , Muscle Fibers, Skeletal/metabolism , Sarcopenia/metabolism , Thioctic Acid/pharmacology , Valerates/pharmacology , Animals , Biomarkers , Cell Line , Cell Survival/drug effects , Cells, Cultured , Dexamethasone/pharmacology , Fluorescent Antibody Technique , Mice , Muscle, Skeletal/drug effects , Muscular Atrophy/drug therapy , Muscular Atrophy/etiology , Muscular Atrophy/metabolism , Myoblasts/drug effects , Oxidative Stress , Sarcopenia/drug therapy , Sarcopenia/etiology
2.
Toxicol In Vitro ; 48: 159-169, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29408665

ABSTRACT

Cadmium (Cd), a worldwide occupational pollutant, is an extremely toxic heavy metal, capable of damaging several organs, including the brain. Its toxicity has been related to neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. The neurotoxic potential of Cd has been attributed to the changes induced in the brain enzyme network involved in counteracting oxidative stress. On the other hand, it is also known that trace elements, such as zinc (Zn) and selenium (Se), required for optimal brain functions, appears to have beneficial effects on the prevention of Cd intoxication. Based on this protective effect of Zn and Se, we aimed to investigate whether these elements could protect neuronal cells from Cd-induced excitotoxicity. The experiments, firstly carried out on SH-SY5Y catecholaminergic neuroblastoma cell line, demonstrated that the treatment with 10 µM cadmium chloride (CdCl2) for 24 h caused significant modifications both in terms of oxidative stress and neuronal sprouting, triggered by endoplasmic reticulum (ER) stress. The evaluation of the effectiveness of 50 µM of zinc chloride (ZnCl2) and 100 nM sodium selenite (Na2SeO3) treatments showed that both elements were able to attenuate the Cd-dependent neurotoxicity. However, considering that following induction with retinoic acid (RA), the neuroblastoma cell line undergoes differentiation into a cholinergic neurons, our second aim was to verify the zinc and selenium efficacy also in this neuronal phenotype. Our data clearly demonstrated that, while zinc played a crucial role on neuroprotection against Cd-induced neurotoxicity independently from the cellular phenotype, selenium is ineffective in differentiated cholinergic cells, supporting the notion that the molecular events occurring in differentiated SH-SY5Y cells are critical for the response to specific stimuli.


Subject(s)
Cadmium Poisoning/prevention & control , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Selenium/pharmacology , Zinc/pharmacology , Apoptosis/drug effects , Caspase 3/metabolism , Cell Differentiation/drug effects , Cell Line , Cell Survival/drug effects , Endoplasmic Reticulum Stress/drug effects , Humans , Neurites/drug effects , Neurons/drug effects , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , Tretinoin/pharmacology
3.
Eur J Med Chem ; 146: 47-59, 2018 Feb 25.
Article in English | MEDLINE | ID: mdl-29407972

ABSTRACT

Human carbonic anhydrases (hCAs, EC 4.2.1.1) IX and XII are overexpressed in a wide variety of cancers and are considered available drug targets for anti-tumor therapy since their inhibition has been shown to reduce tumor growth and metastasis. A set of coumarin derivatives (1-10) and several 1-aryl and 2-aryl-substituted chromeno[4,3-c]pyrazol-4-ones (11-37) and pyrano[4,3-c]pyrazol-4-ones (38-39) were synthesized and tested against the tumor-associated hCAs IX and XII and the cytosolic isoforms hCAs I and II. Several compounds were potent (Ki < 41 nM) and selective inhibitors of the hCA IX (13, 14, 19, 21, 25, 31, 33, 37 and 39), some derivatives (6, 11 and 17) were active against both hCA IX and XII isoforms (Ki = 5.6-9.6 nM), while none were effective against the off-target cytosolic hCAs I and II. Some selected inhibitors (6, 11, 13, 19, 21, 25, 31 and 39) showed activity as antiproliferative agents on HT-29 colon cancer cell lines both in normoxic and hypoxic conditions. This finding led us to hypothesize for these derivatives more than one mechanism of action, involving hCAs IX and XII inhibition in hypoxia and other not identified target(s) in normoxia.


Subject(s)
Antineoplastic Agents/pharmacology , Carbonic Anhydrase IV/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Carbonic Anhydrases/metabolism , Chromones/pharmacology , Coumarins/pharmacology , Pyrazolones/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Carbonic Anhydrase IV/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Cell Proliferation/drug effects , Cell Survival/drug effects , Chromones/chemical synthesis , Chromones/chemistry , Coumarins/chemical synthesis , Coumarins/chemistry , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , HT29 Cells , Humans , Molecular Structure , Pyrazolones/chemical synthesis , Pyrazolones/chemistry , Structure-Activity Relationship , Tumor Cells, Cultured
4.
Neuropharmacology ; 131: 166-175, 2018 03 15.
Article in English | MEDLINE | ID: mdl-29241656

ABSTRACT

Oxaliplatin therapy of colorectal cancer induces a dose-dependent neuropathic syndrome in 50% of patients. Pharmacological treatments may offer limited relief; scientific efforts are needed for new therapeutic approaches. Therefore we evaluated in a preclinical setting the pain relieving properties of mesenchymal stem cells and its secretome. Rat adipose stem cells (rASCs) were administered in a rat model of oxaliplatin-induced neuropathy. A single intravenous injection of rASCs reduced oxaliplatin-dependent mechanical hypersensitivity to noxious and non-noxious stimuli taking effect 1 h after administration, peaking 6 h thereafter and lasting 5 days. Cell-conditioned medium was ineffective. Repeated rASCs injections every 5 days relieved pain each time with a comparable effect. Labeled rASCs were detected in the bloodstream 1 and 3 h after administration and found in the liver 24 h thereafter. In oxaliplatin-treated rats, the plasma concentration of vascular endothelial growth factor (pan VEGF-A) was increased while the isoform VEGF165b was upregulated in the spinal cord. Both alterations were reverted by rASCs. The anti-VEGF-A monoclonal antibody bevacizumab (intraperitoneally) reduced oxaliplatin-dependent pain. Studying the peripheral and central role of VEGF165b in pain, we determined that the intraplantar and intrathecal injection of the growth factor induced a pro-algesic effect. In the oxaliplatin neuropathy model, the intrathecal infusion of bevacizumab, anti-rat VEGF165b antibody and rASCs reduced pain. Adult adipose mesenchymal stem cells could represent a novel approach in the treatment of neuropathic pain. The regulation of VEGF-A is suggested as an effective mechanism in the complex response orchestrated by stem cells against neuropathy.


Subject(s)
Adipose Tissue/cytology , Cell- and Tissue-Based Therapy/methods , Neuralgia/chemically induced , Neuralgia/therapy , Stem Cells/physiology , Vascular Endothelial Growth Factor A/metabolism , Angiogenesis Inhibitors/therapeutic use , Animals , Antineoplastic Agents/toxicity , Bevacizumab/therapeutic use , Cytokines/metabolism , Disease Models, Animal , Hyperalgesia/drug therapy , Injections, Spinal , Male , Organoplatinum Compounds/toxicity , Oxaliplatin , Pain Measurement , Rats , Rats, Sprague-Dawley , Rats, Wistar , Vascular Endothelial Growth Factor A/therapeutic use
5.
ACS Med Chem Lett ; 8(12): 1314-1319, 2017 Dec 14.
Article in English | MEDLINE | ID: mdl-29259754

ABSTRACT

Incorporation of the purine/pyrimidine moieties as tails to classical benzenesulfonamide scaffolds afforded two series of human (h) carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. The compounds were designed according to the molecular hybridization approach, in order to modulate the interaction with different CA isozymes and exploit the antitumor effect of uracil and adenine derivatives in parallel and synergic mode to the inhibition of the tumor-associated hCA IX. The sulfonamides were investigated as inhibitors of four isoforms, cytosolic hCA I/II and transmembrane hCA IV/IX. The inhibitory profiles were dependent on the length and positioning of the spacer connecting the two pharmacophores. X-ray crystallography demonstrated the binding mode of an inhibitor to hCA II and hCA IX-mimic. Compounds endowed with the best hCA IX inhibitory efficacy were evaluated for antiproliferative activity against HT-29 colon cancer cell lines. The in vitro results suggest multiple mechanisms of action are responsible for the compounds' cytotoxic efficacy.

6.
Z Naturforsch C J Biosci ; 72(11-12): 449-457, 2017 Oct 26.
Article in English | MEDLINE | ID: mdl-28822987

ABSTRACT

Lepidium meyenii (Walp.), commonly called maca, is an Andean crop belonging to the Brassicaceae family. Maca hypocotils are habitually consumed as customary food as well as traditional remedies for pathological conditions such as infertility. Moreover, the characterization of maca extracts revealed the presence of compounds that are able to modulate the nervous system. Aimed to evaluate the efficacy of L. meyenii in persistent pain, the present study analyzed the effects of a commercial root extract from maca in different animal models reproducing the most common causes of chronic painful pathologies. A qualitative characterization of this commercial extract by high performance liquid chromatography-mass spectrometry and tandem mass spectrometry analyses allowed us to confirm the presence of some macamides known as bioactive constituents of this root and the absence of the main aromatic glucosinolates. The acute oral administration of maca extract is able to reduce mechanical hypersensitivity and postural unbalance induced by the intra-articular injection of monoiodoacetate and the chronic-constriction injury of the sciatic nerve. Furthermore, L. meyenii extract reverts pain threshold alterations evoked by oxaliplatin and paclitaxel. A good safety profile in mice and rats was shown. In conclusion, the present maca extract could be considered as a therapeutic opportunity to relieve articular and neuropathic pain.


Subject(s)
Analgesics/pharmacology , Chronic Pain/drug therapy , Hyperalgesia/drug therapy , Palmitic Acids/pharmacology , Phytotherapy , Polyunsaturated Alkamides/pharmacology , Sciatica/drug therapy , Administration, Oral , Analgesics/isolation & purification , Animals , Chronic Pain/chemically induced , Chronic Pain/physiopathology , Disease Models, Animal , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Injections, Intra-Articular , Iodoacetic Acid , Male , Organoplatinum Compounds , Oxaliplatin , Paclitaxel , Palmitic Acids/isolation & purification , Plant Extracts/chemistry , Plant Roots/chemistry , Polyunsaturated Alkamides/isolation & purification , Postural Balance/drug effects , Postural Balance/physiology , Rats , Rats, Sprague-Dawley , Sciatic Nerve/drug effects , Sciatic Nerve/injuries , Sciatica/physiopathology , Sciatica/surgery , Water/chemistry
7.
J Med Chem ; 60(14): 6428-6439, 2017 07 27.
Article in English | MEDLINE | ID: mdl-28658574

ABSTRACT

In this paper, we describe the discovery of the 3-hydroxyquinazoline-2,4-dione as a useful scaffold to obtain potent inhibitors of the tumor-associated human carbonic anhydrases (hCAs) IX and XII. A set of derivatives (1-29), bearing different substituents on the fused benzo ring (Cl, NO2, NH2, CF3, ureido, amido, heterocycles), were synthesized, and several of them showed nanomolar activity in inhibiting the hCA IX and XII isoforms, while they were ineffective against the cytosolic enzymes hCAs I and II. Some selected compounds were tested for their antiproliferative activity against HT-29 colon cancer cell lines. After 48 h of treatment with the lower dose (30 µM), derivatives 12, 14, 15, and 19 were significantly active, inducing a mortality by about 50% in both normoxia and hypoxia. This finding led us to hypothesize for these compounds more than one mechanism of action involving both CAs IX and XII and other not yet identified target(s).


Subject(s)
Antineoplastic Agents/chemistry , Carbonic Anhydrase IX/metabolism , Carbonic Anhydrase Inhibitors/chemistry , Carbonic Anhydrases/metabolism , Quinazolines/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/pharmacology , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/pharmacology , Cell Hypoxia , Cell Survival/drug effects , Drug Screening Assays, Antitumor , HT29 Cells , Humans , Quinazolines/chemical synthesis , Quinazolines/pharmacology , Structure-Activity Relationship
8.
J Ethnopharmacol ; 193: 456-465, 2016 Dec 04.
Article in English | MEDLINE | ID: mdl-27647009

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Capparis spinosa L. originates from dry regions of Asia and Mediterranean basin. In traditional medicine of these areas, infusions from caper root are considered to be beneficial for the treatment of rheumatism, gout and against abdominal pains. AIM OF THE STUDY: To evaluate the pain relieving properties of a Syrian cultivar of Capparis spinosa roots in rat models of osteoarthritis and rheumatoid arthritis. MATERIALS AND METHODS: Decoction (DEC) and hydroalcoholic extract (EtH2O) were obtained from powdered roots; the latter was further separated in CH2Cl2 and aqueous (H2O-Res) fractions. The extracts were characterized in terms of spermidine alkaloids by HPLC/DAD/MS and stachydrine by NMR. Different amount of free and glycosilated forms of capparispine and analogues (from 0.5% w/w for DEC up to 7.6% w/w for CH2Cl2 fraction) were detected. Rat models of rheumatoid arthritis and osteoarthritis were induced by the intra-articular administration of Complete Freund's Adjuvant (CFA) or monosodium iodoacetate (MIA), respectively. RESULTS: Fourteenth days after CFA or MIA injection, the different preparations of Capparis spinosa (3, 30, 100 and 300mgkg-1) were acutely administered p.o.. Powdered roots (300mgkg-1), DEC (100mgkg-1), and EtH2O (300mgkg-1) significantly reduced hypersensitivity to mechanical noxious stimuli as well as spontaneous pain evaluated as hind limb bearing alterations in both models. The CH2Cl2 and the H2O-Res (30mgkg-1) were the most potent in reverting pain threshold alterations despite the different content of free alkaloids. CONCLUSIONS: Capparis spinosa extracts relieved pain related to rheumatoid arthritis and osteoarthritis after single administration. A synergistic effect due to a specific "phytochemical mixture" is suggested.


Subject(s)
Analgesics/pharmacology , Arthritis, Experimental/drug therapy , Arthritis, Rheumatoid/drug therapy , Capparis/chemistry , Hyperalgesia/drug therapy , Osteoarthritis/drug therapy , Pain Threshold/drug effects , Plant Extracts/pharmacology , Plant Roots/chemistry , Administration, Oral , Alkaloids/isolation & purification , Alkaloids/pharmacology , Analgesics/administration & dosage , Analgesics/isolation & purification , Animals , Arthritis, Experimental/chemically induced , Arthritis, Experimental/physiopathology , Arthritis, Experimental/psychology , Arthritis, Rheumatoid/chemically induced , Arthritis, Rheumatoid/physiopathology , Arthritis, Rheumatoid/psychology , Behavior, Animal/drug effects , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Freund's Adjuvant , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Hyperalgesia/psychology , Iodoacetic Acid , Male , Osteoarthritis/chemically induced , Osteoarthritis/physiopathology , Pain Measurement , Phytotherapy , Plant Extracts/administration & dosage , Plant Extracts/isolation & purification , Plants, Medicinal , Proton Magnetic Resonance Spectroscopy , Rats, Sprague-Dawley , Solvents/chemistry , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Time Factors
9.
Phytomedicine ; 22(7-8): 752-8, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-26141762

ABSTRACT

BACKGROUND: Tanacetum parthenium L., commonly called Feverfew, is known for anti-inflammatory and anti-migraine properties. PURPOSE: Aimed to individuate new therapeutical strategies to control acute and persistent pain induced by different origins we tested two hydroalcoholic extracts obtained from Feverfew flowers and leaves, respectively. STUDY DESIGN: Extracts were characterized according to the European Pharmacopoeia monograph. Both the extracts were tested after acute per os administration in the dose range 30-1000 mg kg(-1). The anti-nociceptive properties were evaluated by the Writhing test in mice. RESULTS: The number of abdominal contractions was dose dependently reduced by the flower extract. It reduced mechanical hypersensitivity (Paw pressure test) related to the acute inflammatory phase induced by carrageenan similarly to diclofenac and ibuprofen. In the osteoarthritis model induced by intra articular injection of monoiodoacetate (MIA) the flower extract significantly increased the pain threshold peaking 30 min after treatment. Moreover, it was effective in the chronic constriction injury model of neuropathic pain showing activity similar to the anti-epileptic drug gabapentin. The flower extract activity was confirmed in rat models of chemotherapy-induced neuropathic pain. The mechanical hypersensitivity induced by repeated treatments with the anticancer drug oxaliplatin and with the antiviral dideoxycytidine was significantly reduced after a single injection of Feverfew flower extract. The leaf extract showed lesser efficacy and potency and it was devoid of any effect in carrageenan-, MIA- and chemotherapy-induced pain. CONCLUSION: The present Feverfew flower extract behaves as a potent pain reliever in acute, inflammatory, articular and neuropathic pain. It appears as a natural strategy potentially suitable for the treatment of different kinds of pain.


Subject(s)
Analgesics/pharmacology , Flowers/chemistry , Pain/drug therapy , Plant Extracts/pharmacology , Tanacetum parthenium/chemistry , Animals , Anti-Inflammatory Agents/pharmacology , Male , Mice , Plant Leaves/chemistry , Rats , Rats, Sprague-Dawley
10.
Neural Plast ; 2015: 396908, 2015.
Article in English | MEDLINE | ID: mdl-26146570

ABSTRACT

Neuropathies are characterized by a complex response of the central nervous system to injuries. Glial cells are recruited to maintain neuronal homeostasis but dysregulated activation leads to pain signaling amplification and reduces the glial neuroprotective power. Recently, we highlighted the property of α7 nicotinic-acetylcholine-receptor (nAChR) agonists to relieve pain and induce neuroprotection simultaneously with a strong increase in astrocyte density. Aimed to study the role of α7 nAChR in the neuron-glia cross-talk, we treated primary rat neurons and astrocytes with the neurotoxic anticancer drug oxaliplatin evaluating the effect of the α7 nAChR agonist PNU-282987 (PNU). Oxaliplatin (1 µM, 48 h) reduced cell viability and increased caspase-3 activity of neuron monocultures without damaging astrocytes. In cocultures, astrocytes were not able to protect neurons by oxaliplatin even if glial cell metabolism was stimulated (pyruvate increase). On the contrary, the coculture incubation with 10 µM PNU improved neuron viability and inhibited apoptosis. In the absence of astrocytes, the protection disappeared. Furthermore, PNU promoted the release of the anti-inflammatory cytokine TGF-ß1 and the expression of the glutamate-detoxifying enzyme glutamine synthetase. The α7 nAChR stimulation protects neurons from oxaliplatin toxicity through an astrocyte-mediated mechanism. α7 nAChR is suggested for recovering the homeostatic role of astrocytes.


Subject(s)
Astrocytes/metabolism , Cerebral Cortex/metabolism , Neurons/metabolism , Organoplatinum Compounds/toxicity , alpha7 Nicotinic Acetylcholine Receptor/metabolism , Animals , Astrocytes/drug effects , Astrocytes/enzymology , Benzamides/pharmacology , Bridged Bicyclo Compounds/pharmacology , Cell Survival/drug effects , Cerebral Cortex/drug effects , Glutamate-Ammonia Ligase/metabolism , Neurons/drug effects , Oxaliplatin , Primary Cell Culture , Pyruvic Acid/analysis , Rats , Rats, Sprague-Dawley , Transforming Growth Factor beta1/analysis , alpha7 Nicotinic Acetylcholine Receptor/agonists
SELECTION OF CITATIONS
SEARCH DETAIL
...